AMBICION collaborates with Keio University Hospital and RIKEN on the clinical trial of the newly developed Natural Killer T (NKT) cell targeted anti-cancer therapy
March 12, 2018
AMBICION starts to supply the investigational product to a phase I study of the newly developed Natural Killer T (NKT) cell-targeted anti-cancer therapy conducted by Keio University Hospital. This clinical trial evaluates the safety and efficacy of an investigational product that activates patient i...